Close Menu

NEW YORK – Molecular diagnostics firm Agendia has settled with the US government for $8.25 million over allegations of Medicare fraud, the US Department of Justice, Western District of Kentucky announced on Wednesday.

The DOJ alleged that the company, which has offices in the Netherlands and Irvine, California, conspired with hospitals to "artificially delay" ordering the firm's MammaPrint genetic test for breast cancer in order to circumvent Medicare's 14-day rule, which determines who can bill Medicare for certain lab services.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

CNN reports that a US Food and Drug Administration document says Johnson & Johnson's SARS-CoV-2 vaccine meets the requirements to receive an Emergency Use Authorization.

According to BBC News, the global vaccine-sharing initiative has sent its first shipment, which arrived in Ghana this week.

Researchers in France are developing a new, fast test for SARS-CoV-2 that initial testing indicates may be highly accurate, the Guardian says.

In Cell this week: analysis of fitness patterns among SARS-CoV-2 isolates, single-cell transcriptome analysis of immune features in COVID-19, and more.

Feb
25
Sponsored by
Foundation Medicine

In this session, the second in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review cases in which patient genomic profiles exhibit common driver mutations in tumor types considered “off label” for targeted therapies associated with those mutations.

Mar
17
Sponsored by
IONPath

In this webinar, Felix J. Hartmann of Stanford University will describe an approach that characterizes the metabolic regulome of individual cells together with their phenotypic identity.